VitaSpring Biomedical Co (VSBC) Financials
Newest figures come from the 10-Q for Q2 FY2027, filed Sep 17, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VSBC SEC filings page.
VitaSpring Biomedical Co (VSBC) reported $0 in revenue for fiscal year 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2022 profitability did not translate into cash: reported earnings depended on an asset-light balance sheet with meaningful short-term obligations.
Cash conversion was weak: net income was$910K , while operating cash flow was-$270K and free cash flow was-$343K . That gap indicates reported profit was tied up in working-capital movements rather than arriving as spendable operating cash.
Liquidity was functional but not abundant: current assets of
Low reinvestment did not solve cash generation: capital expenditures were only
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
We do not publish a peer-relative financial health score for VitaSpring Biomedical Co, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
VitaSpring Biomedical Co generated $0 in revenue in Q2 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
VitaSpring Biomedical Co earned $0.00 per diluted share (EPS) in Q2 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2027.
Not reported for Q2 2027.
Cash & Balance Sheet
VitaSpring Biomedical Co held $13K in cash as of Q2 2027; no long-term debt figure is on record for that period.
Not reported for Q2 2027.
Not reported for Q2 2027.
Margins & Returns
None of these metrics is reported for Q2 2027.
Capital Allocation
None of these metrics is reported for Q2 2027.
VSBC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0n/m | $0n/m | N/A | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| SG&A Expenses | $6K-3.7% | N/A | N/A | N/A | $6K-97.2% | N/A | N/A | $118K-49.8% |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$118Kn/m |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$115Kn/m |
| Income Tax | $0-100.0% | $0-100.0% | N/A | $7K-91.3% | $12Kn/m | $11Kn/m | N/A | $78Kn/m |
| Net Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$196Kn/m |
| EPS (Diluted) | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m |
| Diluted Shares (Avg) | 207M0.0% | 207M0.0% | N/A | 207M0.0% | 207M0.0% | 207M0.0% | N/A | 207M0.0% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, Interest Expense, EPS (Basic).
VSBC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $15K-12.9% | $11K-4.0% | $15K+2.1% | $16K-71.8% | $17K-73.5% | $12K-90.9% | $14K-89.5% | $58K-78.9% |
| Current Assets | $15K+87.8% | $10K+3212.5% | $11K+3770.2% | $10K-76.5% | $8K-82.6% | $295-99.5% | $272-98.8% | $42K-60.7% |
| Cash & Equivalents | $13Kn/m | $8Kn/m | $2Kn/m | $0-100.0% | $0-100.0% | $0-100.0% | $0n/m | $2K-21.8% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | $0n/m | $0-100.0% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $4.7M+10.7% | $4.5M+10.0% | $4.4M+10.3% | $4.4M+11.1% | $4.2M+12.1% | $4.1M+12.3% | $4.0M+15.5% | $3.9M+14.1% |
| Current Liabilities | $2.3M-46.3% | $4.5M+10.0% | $4.4M+10.3% | $4.4M+11.1% | $4.2M+12.1% | $4.1M+12.3% | $4.0M+15.5% | $3.9M+14.1% |
| Non-Current Liabilities | $2.4Mn/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Equity | -$4.7Mn/m | -$4.5Mn/m | -$4.4Mn/m | -$4.3Mn/m | -$4.2Mn/m | -$4.1Mn/m | -$4.0Mn/m | -$3.9Mn/m |
| Retained Earnings | -$5.9Mn/m | -$5.8Mn/m | -$5.7M-207.9% | -$5.6Mn/m | -$5.5Mn/m | -$5.4Mn/m | $5.3Mn/m | -$5.1Mn/m |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
VSBC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $5Kn/m | $6Kn/m | $124n/m | -$839n/m | -$1Kn/m | -$787n/m | -$2Kn/m | -$6Kn/m |
| Depreciation & Amortization | N/A | $2K0.0% | $2K0.0% | $2K0.0% | $2K0.0% | $2K0.0% | $2K-33.9% | $2K-33.9% |
| Stock-Based Compensation | N/A | N/A | N/A | N/A | N/A | $0-100.0% | N/A | $27K-33.3% |
| Financing Cash Flow | $0-100.0% | $0-100.0% | $0n/m | $2K-32.8% | $2K-71.6% | $515-89.7% | $0n/m | $3Kn/m |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
VSBC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity, FCF Margin.
Note: Shareholder equity is negative (-$4.4M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| VitaSpring Biomedical Co VSBC | FY2026 | $0 | N/A | N/A | $6.6M | — |
| Oncotelic Therapeutcs Inc OTLC | FY2025 | N/A | $249.3M | N/A | $7.6M | — |
| COSCIENS Biopharma Inc CSCIF | FY2025 | $7.5M | -$10.4M | N/A | $6.1M | — |
| OSR Health Inc OSRH | FY2025 | $2.9M | -$18.0M | N/A | $5.6M | — |
Where VitaSpring Biomedical Co Ranks
Frequently Asked Questions
VitaSpring Biomedical Co (VSBC) reported $0 in total revenue for fiscal year 2026. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
VitaSpring Biomedical Co (VSBC) recorded an outflow of $3K in operating cash flow during fiscal year 2026, representing cash used by core business activities.
VitaSpring Biomedical Co (VSBC) had $15K in total assets as of fiscal year 2026, including both current and long-term assets.
VitaSpring Biomedical Co (VSBC) had a current ratio of 0.00 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.
At the end of fiscal year 2026, VitaSpring Biomedical Co (VSBC) held $2K in cash, cash equivalents and investments, and reported an operating cash outflow of $3K over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
VitaSpring Biomedical Co (VSBC) has negative shareholder equity of -$4.4M as of fiscal year 2026, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.